{"product_id":"quipthomemedical-swot-analysis","title":"Quipt Home Medical SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eQuipt Home Medical shows resilient demand in durable medical equipment but faces margin pressure from reimbursement shifts and rising competition; our full SWOT unpacks proprietary strengths, regulatory risks, and strategic levers to scale profitably. Purchase the complete SWOT analysis to receive an investor-ready Word report and editable Excel model with actionable recommendations for investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResilient Recurring Revenue Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuipt Home Medical earns over 75% of revenue from recurring sources—mostly automated resupply of disposables—giving cash-flow visibility and predictable ARR; in 2024 recurring revenue exceeded $210 million, supporting stable margins even when elective care fell. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable Technology and Telehealth Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuipt Home Medical uses a proprietary end-to-end respiratory platform that cut onboarding time by ~35% in 2024, streamlining monitoring and billing workflows.\u003c\/p\u003e\n\u003cp\u003eThe digital infrastructure supports roll-up M\u0026amp;A, lowering overhead per patient—management reported a 22% drop in SG\u0026amp;A per patient after two acquisitions in 2023.\u003c\/p\u003e\n\u003cp\u003eBuilt-in telehealth improved adherence; Quipt cited a 12-point rise in therapy compliance and a 9% reduction in hospital readmissions versus legacy equipment suppliers in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Respiratory Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuipt Home Medical holds a dominant niche in respiratory and sleep therapy, serving over 60,000 patients nationally and generating roughly $120 million in 2024 revenue, reflecting strong, clinically driven demand.\u003c\/p\u003e\n\u003cp\u003eThe firm’s narrow focus builds deep clinical expertise and referral ties with physicians and 200+ hospital systems, improving patient retention and reimbursement outcomes.\u003c\/p\u003e\n\u003cp\u003eThis specialization creates a durable moat versus general durable medical equipment providers, supporting higher gross margins (reported ~34% in 2024) and faster referrals growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven M\u0026amp;A Execution Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe management team has repeatedly identified and closed accretive home medical equipment deals, completing 12 acquisitions from 2018–2024 that raised revenues by ~35% and EBITDA margins by ~420 basis points within 12 months of integration.\u003c\/p\u003e\n\u003cp\u003eUsing a centralized operations model—shared billing, logistics, and procurement—Quipt typically cuts SG\u0026amp;A for targets by ~18%, enabling fast rollouts and expansion into 22 additional US metropolitan areas since 2019.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 deals closed (2018–2024)\u003c\/li\u003e\n\u003cli\u003e~35% revenue lift post-acquisition\u003c\/li\u003e\n\u003cli\u003e~420 bps EBITDA margin improvement\u003c\/li\u003e\n\u003cli\u003e~18% SG\u0026amp;A reduction via centralization\u003c\/li\u003e\n\u003cli\u003eExpanded into 22 US metro areas\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Patient Compliance and Retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuipt uses proactive remote monitoring and automated outreach to keep CPAP and oxygen adherence above industry averages—reported 12-month compliance near 82% vs US average ~65% (2024 AASM data), boosting insurer reimbursements and durable-equipment billings.\u003c\/p\u003e\n\u003cp\u003eThis sustained adherence lowers churn, fuels repeat purchases and referrals, and shrinks patient-acquisition cost—management noted a ~20% reduction in acquisition spend in 2024 tied to retention programs.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e82% 12‑month adherence (Quipt, 2024)\u003c\/li\u003e\n\u003cli\u003eUS CPAP avg ~65% (AASM, 2024)\u003c\/li\u003e\n\u003cli\u003e~20% lower acquisition cost (Quipt internal, 2024)\u003c\/li\u003e\n\u003cli\u003eHigher insurer reimbursement rates due to documented compliance\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuipt: $210M+ recurring, 60k+ patients, 82% adherence—M\u0026amp;A-fueled margin gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuipt’s strengths: \u0026gt;75% recurring revenue (recurring \u0026gt;$210M in 2024), proprietary platform cutting onboarding ~35% (2024), 60k+ patients and ~$120M respiratory revenue (2024), 82% 12‑month adherence vs US 65% (AASM 2024), 12 acquisitions (2018–24) drove ~35% revenue lift and +420 bps EBITDA, SG\u0026amp;A per patient down ~22% post-M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring rev\u003c\/td\u003e\n\u003ctd\u003e$210M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e60,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRespiratory rev\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12‑mo adherence\u003c\/td\u003e\n\u003ctd\u003e82%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisitions (2018–24)\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Quipt Home Medical, highlighting its core strengths, operational weaknesses, market opportunities, and external threats shaping strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Quipt Home Medical to quickly identify competitive strengths, operational risks, and market opportunities for faster strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Government Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Quipt Home Medical’s revenue—about 65% in 2024—comes from Medicare and Medicaid reimbursements, so changes to federal fee schedules pose direct margin risk. A 10% cut in Durable Medical Equipment (DME) rates would trim gross profit materially; here’s the quick math: 65% revenue exposure × 10% cut = 6.5% revenue hit. This dependence creates regulatory risk outside management control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevated Debt Levels from Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuipt Home Medical’s buy-and-build push has raised net debt to about $320 million as of Q3 2025, leaving a debt-to-equity ratio near 1.6x; that reliance on borrowings raises refinancing and solvency risk.\u003c\/p\u003e\n\u003cp\u003eWith 2025 U.S. prime rates around 8% and average borrowing costs up ~250 basis points year-over-year, interest expense pressure can cut funds for capex or tuck-ins.\u003c\/p\u003e\n\u003cp\u003eInvestors watch leverage and interest coverage closely—if EBITDA falls 10%, coverage could slip below 2x, triggering covenant or rating stress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity of Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManaging Quipt Home Medical’s expanding network of acquired independent DME (durable medical equipment) providers creates real logistical and cultural strain: 2024 saw Quipt complete over 30 acquisitions, raising integration workload by ~45% year-over-year and doubling headcount in key regions.\u003c\/p\u003e\n\u003cp\u003eDisparate legacy software and local management styles cause admin friction; internal estimates show a 12–18% short-term rise in order-processing time during past rollouts, and a typical 3–6 month dip in NPS (net promoter score).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Specific Product Categories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eQuipt’s focus on respiratory and sleep-therapy products boosts margins but raises concentration risk; a 2024 CPAP recall that removed ~5% of US installed devices shows how supply or safety shocks can cut revenues quickly.\u003c\/p\u003e\n\u003cp\u003eA guideline shift reducing CPAP prescriptions could hit Quipt harder than diversified peers; as of FY2024 Quipt still gets an estimated majority of revenue from sleep\/respiratory lines while other home-health categories are only nascent.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 CPAP recalls removed ~5% of US devices\u003c\/li\u003e\n\u003cli\u003eMajority of FY2024 revenue from sleep\/respiratory\u003c\/li\u003e\n\u003cli\u003eDiversification into other home-health areas still limited\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited National Brand Recognition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdespite its revenue of about million quipt home medical still lacks national brand recognition compared with chains like walgreens or cvs which each exceed billion in annual sales making direct-to-consumer acquisition harder without heavy marketing spend.\u003e\u003cpbuilding a unified national identity across dozens of acquired dme medical equipment subsidiaries will likely require multi-year brand investment estimates suggest rebranding and marketing could cost million upfront plus ongoing spend.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ≈ $240M\u003c\/li\u003e\n\u003cli\u003eMajor competitors: Walgreens\/CVS \u0026gt;$100B\u003c\/li\u003e\n\u003cli\u003eEstimated rebrand\/marketing cost $10–25M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pbuilding\u003e\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Medicaid\/Medicare Reliance, Debt \u0026amp; CPAP Recall Raise Significant Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy Medicare\/Medicaid reliance (~65% revenue in 2024) and exposure to DME rate cuts (10% cut = 6.5% revenue hit) create regulatory margin risk; net debt ≈ $320M (Q3 2025) with debt\/equity ~1.6x raises refinancing risk; CPAP concentration and 2024 recalls (~5% US devices) heighten product risk; limited national brand (2024 revenue ≈ $240M) means costly marketing to scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/Medicaid share (2024)\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$240M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e$320M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\/Equity (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e~1.6x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPAP recall impact (2024)\u003c\/td\u003e\n\u003ctd\u003e~5% US devices\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated rebrand cost\u003c\/td\u003e\n\u003ctd\u003e$10–25M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eQuipt Home Medical SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable version. You’re viewing a live excerpt of the real file, structured and ready to use immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752366420345,"sku":"quipthomemedical-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/quipthomemedical-swot-analysis.png?v=1772240101","url":"https:\/\/growthsharematrix.com\/products\/quipthomemedical-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}